clinical trial · NCT05112965
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
NeoplasmsAtezolizumabBevacizumabPemetrexedPaclitaxelEnzalutamide
brief summary
This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.
started
Dec 1, 2021
primary completion
Jun 30, 2027
completion
Jun 30, 2027
last updated
Sep 30, 2026
official title
An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol